ArticleEuropean clinical respiratory journal2025
Serologically assessed markers of fibroblast activity (PRO-C3 and PRO-C6) and risk assessment of pulmonary fibrosis following severe COVID-19 infection.
Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An update on the landscape of collagen bioactive fragments.The FEBS journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impaired lung function and fibrotic scarring of the lungs following severe COVID-19 infection are well-known manifestations. However, the risk factors and predisposing factors are still unknown. This study explored whether serological biomarkers for collagen synthesis associate with impaired lung function and fibrotic scarring after COVID-19 infection. Methods: In a prospective, observational cohort study involving patients hospitalized with COVID-19 requiring intensive care from June 2020 to December 2021, patients were followed up at 1, 3, 6, and 12 months after discharge. Lung function, diffusion capacity, and a panel of serological biomarkers for collagen-based fibrogenesis (PRO-C3, PRO-C6, and PRO-FIB) were measured. Additionally, a high-resolution CT scan of the lungs was performed at 3 and 12 months. Results: Thirty-four patients were included in the study. Twenty-seven (80%) were men (mean age 61 years). Most patients were former or active smokers (56%), while 44% were never smokers. Levels of both PRO-C3, PRO-C6, and PRO-FIB were higher 3 months after discharge compared to the normal range. The highest levels were measured 1 month after discharge, with PRO-C3 23.2 ng/ml, PRO-C6 15.9 ng/ml, and PRO-FIB 29.3 ng/ml. The levels of PRO-C3 declined up to 6 months after discharge and were hereafter stabilized, whereas the levels of PRO-C6 declined for the entire follow up period. Lung function improved during the first 6 months and then stabilized. Comparing lung function with PRO-C3 and PRO-C6 showed a positive correlation with lung function improving, while levels of the biomarkers declined. However, only PRO-C3 was found to be significantly associated with improvement in lung function 1 month after discharge. Conclusions: This study found that PRO-C3 and PRO-C6 are associated with changes in lung function after severe COVID-19 infection. High levels of both PRO-C6 and PRO-C3 were found up to 6 months after discharge in patients with impaired lung function, however, the values declined towards reference levels after 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.